 CAMBRIDGE, Mass., Sept. 20, 2021 GLOBE NEWSWIRE -- Solid Biosciences Inc. Nasdaq: SLDB, a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy Duchenne, today announced that Joel Schneider, Ph.D., Chief Operating Officer, and Carl Morris, Ph.D., Chief Scientific Officer, will participate at the SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases Genetic Medicines 1x1 Event and Chardans 5th Annual Genetic Medicines Conference. 